Assessing the predictive value of intraductal carcinoma of the prostate (IDC‐P) in determining abiraterone efficacy for metastatic hormone‐sensitive prostate cancer (mHSPC) patients
This study found that IDC-P, especially pattern 2, predicts poor prognosis in mHSPC patients on abiraterone therapy. Also, abiraterone's advantage over hormone therapy is reduced in cases with IDC-P compared to those without.
Authors
- Jinge Zhao (ORCID: https://orcid.org/0000-0002-2790-462X)
- Jiayu Liang
- Pengfei Shen (ORCID: https://orcid.org/0000-0002-0370-0411)
- Xu Hu (ORCID: https://orcid.org/0000-0003-4306-4656)
- Ling Nie (ORCID: https://orcid.org/0000-0002-7878-2001)
- Xinyuan Wei (ORCID: https://orcid.org/0000-0001-9337-333X)
- Guangxi Sun (ORCID: https://orcid.org/0000-0003-3719-2643)
- Yu Shen (ORCID: https://orcid.org/0000-0002-0167-458X)
- Junru Chen (ORCID: https://orcid.org/0000-0003-4553-6979)
- Hao Zeng (ORCID: https://orcid.org/0000-0003-0818-8151)
- Zhenhua Liu (ORCID: https://orcid.org/0000-0003-1926-6020)
- Ni Chen (ORCID: https://orcid.org/0000-0002-0628-0723)
- Shi Yi-fu
- Xingming Zhang (ORCID: https://orcid.org/0000-0001-8239-5410)
- Fengnian Zhao
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
Publication Details
- Journal
- The Prostate
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1002/pros.24809
- Citations
- 2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- Bethune Charitable Foundation
- National Natural Science Foundation of China
- Sichuan University
- Chinese Academy of Medical Sciences
- West China Hospital, Sichuan University